Technologies, Products and Services

URC has a history of improving the quality of healthcare delivery, including improvements at all levels of the health system—in communities, health centers, hospitals, villages, districts, provinces, and at the national level.

Phenotypic detection of resistance to beta-lactam antimicrobials in a rapid lateral flow test with no need for sample culture

Transdisciplinary research network

The TRA-COAT project combats implant infections with a novel coating, featuring antibiofilm activity and triggered antimicrobial release. It focuses on orthopaedic and vascular implants, enhancing durability and reducing resistance development.

Evotec leverages advanced platforms, including AI-driven drug discovery, high-throughput screening, and molecular design, to accelerate the development of therapies targeting bacteria, viruses, and fungi from early discovery to clinical stages.

Bismocin an inhaled low-dose CBS therapy, enhances antibiotics to treat resistant P. aeruginosa. Safe, low-cost, and non-competitive with current care, it prevents biofilms and resistance, offering targeted, effective lung infection treatment.

Chemical-free physical surface that reduces bacterial adhesion and biofilm formation

Researchers and public health institutes worldwide use our Biomark X9 microfluidics genomics system to monitor multiple ARGs and pathogens simultaneously with a high-throughput, flexible, and robust protocol

Software plays a pivotal role in delivering innovative solutions for diagnostics, treatment, and management to improve patient care and outcomes.

LeadtoTreat aims to develop a platform for future treatment of multidrug-resistant microbial infections, enabling targeted delivery of novel lead compounds with low drugability, as well as synergistic combinations of antibiotics in a nanoformulation

Innovative and disruptive development of bio active peptides

AMR screening facility HG2/3 https://warwick.ac.uk/fac/cross_fac/amrscreening/

The Centre develops electrochemical biosensor platforms designed for specific use cases. These are generally underpinned by gold or carbon electrodes and involve the use of affinity reagents such as aptamers and antibodies.

The Cerashield biofilm resistant endotracheal tube is designed to reduce potentially lethal respiratory infections among mechanically ventilated ICU patients.

The o~pal CRP test matches the performance of comparator commercialised tests at a lower cost, and with the benefit of digital connectivity. Future plans include building out the test with additional analytes such as markers of antibiotic resistance.

1) Large Language Models for Microbiota & 2) AI peptide modelling in AMR

Holographic identification of mechanism of action of a drug

QuickRPA leverages Python programming to create scripts that automate repetitive tasks. It combines simplicity and versatility with automation frameworks, enabling seamless integration with various systems and applications for efficient automation.

PepDRED transforms peptide design by integrating advanced computational tools into an intuitive platform for non-computational biologists. It enables precise control of peptide modifications, fostering innovation in peptide development

Profound knowledge and expertise in Middle East AMS

Our service in relation to antimicrobial resistance evolves around implementing, in projects where we work: infection prevention and control protocols, antimicrobial stewardship and microbiology laboratories to improve treatment and diagnostics

A complete instrumentation system for automating the analysis of urine sample for UTI pathogen and reporting of AST and ID in 96 microwell plate.

Our models allow us to accurately map cellular biochemistry at extremely high levels of resolution, which we use to identify the best drug targets whilst also confirming that cells cannot bypass their inhibition.

Mast Group Ltd. is an independent world class manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing.